Nicole L. Stone
About
Nicole L. Stone is a scholar working on Hematology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Nicole L. Stone has authored 44 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 13 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Nicole L. Stone's work include Platelet Disorders and Treatments (16 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Blood properties and coagulation (6 papers). Nicole L. Stone is often cited by papers focused on Platelet Disorders and Treatments (16 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Blood properties and coagulation (6 papers). Nicole L. Stone collaborates with scholars based in United States, United Kingdom and Hong Kong. Nicole L. Stone's co-authors include Saoirse E. O’Sullivan, Randall N. Pittman, Jason C. Mills, James B. Bussel, Bhabita Mayer, M. Arning, Gregory Cheng, Sophie Millar, Andrew Yates and Timothy J. England and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.
In The Last Decade
Nicole L. Stone
42 papers receiving 3.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nicole L. Stone United States | 20 | 1.5k | 727 | 625 | 397 | 381 | 44 | 3.4k | ||
| Albert Smolenski Germany | 37 | 556 0.4× | 2.6k 3.6× | 207 0.3× | 292 0.7× | 328 0.9× | 67 | 5.0k | ||
| Julia Nguyen United States | 33 | 760 0.5× | 1.2k 1.7× | 229 0.4× | 125 0.3× | 319 0.8× | 87 | 3.3k | ||
| James L. Daniel United States | 34 | 1.5k 1.0× | 1.3k 1.8× | 231 0.4× | 80 0.2× | 318 0.8× | 81 | 3.7k | ||
| Nobuhito Goda Japan | 35 | 652 0.4× | 2.6k 3.6× | 165 0.3× | 308 0.8× | 423 1.1× | 80 | 4.8k | ||
| Junji Nishimura Japan | 36 | 925 0.6× | 2.7k 3.7× | 161 0.3× | 370 0.9× | 508 1.3× | 276 | 5.6k | ||
| Paul Schaeffer France | 27 | 539 0.4× | 1.8k 2.4× | 292 0.5× | 100 0.3× | 423 1.1× | 73 | 3.9k | ||
| Carlos D. Figueroa Chile | 29 | 686 0.5× | 1.4k 1.9× | 264 0.4× | 180 0.5× | 155 0.4× | 93 | 4.1k | ||
| Ludovic Martin France | 35 | 214 0.1× | 1.3k 1.7× | 320 0.5× | 606 1.5× | 336 0.9× | 190 | 4.6k | ||
| Hiroyuki Matsuno Japan | 30 | 407 0.3× | 1.2k 1.7× | 186 0.3× | 150 0.4× | 226 0.6× | 133 | 2.7k | ||
| Keiichi Enjyoji United States | 37 | 507 0.3× | 1.1k 1.5× | 132 0.2× | 112 0.3× | 547 1.4× | 80 | 4.9k |
Countries citing papers authored by Nicole L. Stone
Since
Specialization
Citations
This map shows the geographic impact of Nicole L. Stone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicole L. Stone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicole L. Stone more than expected).
Fields of papers citing papers by Nicole L. Stone
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Nicole L. Stone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicole L. Stone. The network helps show where Nicole L. Stone may publish in the future.
Co-authorship network of co-authors of Nicole L. Stone
This figure shows the co-authorship network connecting the top 25 collaborators of Nicole L. Stone. A scholar is included among the top collaborators of Nicole L. Stone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicole L. Stone. Nicole L. Stone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Li, Roger, Gautam Jayram, Angela Girvin, et al.. (2025). MOONRISE-1: PHASE 3 STUDY OF TAR-210, AN ERDAFITINIB INTRAVESICAL TARGETED RELEASING SYSTEM, VERSUS INTRAVESICAL CHEMOTHERAPY IN PATIENTS WITH FGFR-ALTERED INTERMEDIATE-RISK NON–MUSCLE-INVASIVE BLADDER CANCER. Urologic Oncology Seminars and Original Investigations. 43(3). 53–53.
2.
Siefker‐Radtke, Arlene O., Yohann Loriot, Nobuaki Matsubara, et al.. (2024). FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro).. Journal of Clinical Oncology. 42(16_suppl). 4578–4578.
3.
Li, Roger, Ja Hyeon Ku, Antoni Vilaseca, et al.. (2024). Urine-based testing for patient selection and genomic characterization of patients with FGFR alteration-positive non–muscle-invasive bladder cancer (NMIBC) treated with TAR-210.. Journal of Clinical Oncology. 42(4_suppl). 676–676.
4.
Carrasco‐Zevallos, Oscar, Stephen Yip, Patricia Raciti, et al.. (2024). Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial. Nature Communications. 15(1). 4690–4690.
5.
Vilaseca, Antoni, Gautam Jayram, Carles X. Raventós, et al.. (2023). LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt). Annals of Oncology. 34. S1343–S1343.
6.
Loriot, Yohann, Nobuaki Matsubara, Se Hoon Park, et al.. (2023). Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine. 389(21). 1961–1971.
7.
Stone, Nicole L., Timothy J. England, & Saoirse E. O’Sullivan. (2021). Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions. Cannabis and Cannabinoid Research. 6(4). 315–326.
8.
Drake, Charles G., Russell K. Pachynski, Sumit K. Subudhi, et al.. (2021). Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 25(2). 219–228.
9.
Brahmer, Julie R., Melissa L. Johnson, Manuel Cobo, et al.. (2020). JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies. JTO Clinical and Research Reports. 2(2). 100103–100103.
10.
Brahmer, Julie R., Melissa L. Johnson, Manuel Cobo, et al.. (2019). Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.. Journal of Clinical Oncology. 37(15_suppl). 9093–9093.
11.
Stone, Nicole L., Sophie Millar, P Herrod, et al.. (2018). An Analysis of Endocannabinoid Concentrations and Mood Following Singing and Exercise in Healthy Volunteers. Frontiers in Behavioral Neuroscience. 12. 269–269.
12.
Millar, Sophie, Nicole L. Stone, Andrew Yates, & Saoirse E. O’Sullivan. (2018). A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Frontiers in Pharmacology. 9. 1365–1365.
13.
Cheng, Gregory, Mansoor N. Saleh, Claus Werenberg Marcher, et al.. (2010). Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. The Lancet. 377(9763). 393–402.
14.
Bussel, James B., Drew Provan, Tahir Shamsi, et al.. (2009). Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. The Lancet. 373(9664). 641–648.
15.
Psaila, Bethan, J B Bussel, Sandra Y. Vasey, et al.. (2008). EFFICACY AND SAFETY OF REPEATED INTERMITTENT TREATMENT WITH ELTROMBOPAG IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP). 93. 120–120.
16.
Bussel, James B., Bethan Psaila, Mansoor N. Saleh, et al.. (2008). Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura.. Blood. 112(11). 3431–3431.
17.
Cheng, Gregory, James B. Bussel, Mansoor N. Saleh, et al.. (2008). Eltrombopag Delivers Clinical Benefit in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients Not Achieving Platelet Counts ≥50,000/μL - Data from the EXTEND Study.. Blood. 112(11). 3430–3430.
18.
Bussel, J B, Guang‐Shing Cheng, Mohammad Saleh, et al.. (2007). Eltrombopag, an oral platelet growth factor, for treatment of chronic immune thrombocytopenic purpura (ITP): A randomized, double-blind, placebo-controlled trial. 5. 66–67.
19.
Bussel, James B., Gregory Cheng, Mansoor N. Saleh, et al.. (2007). Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura. New England Journal of Medicine. 357(22). 2237–2247.
20.
Wülfing, Christian, J-P. Machiels, Dick J. Richel, et al.. (2005). A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Journal of Clinical Oncology. 23(16_suppl). 4594–4594.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Albert Smolenski Breakdown of academic impact, for papers by Julia Nguyen Breakdown of academic impact, for papers by James L. Daniel Breakdown of academic impact, for papers by Nobuhito Goda Breakdown of academic impact, for papers by Junji Nishimura Breakdown of academic impact, for papers by Paul Schaeffer Breakdown of academic impact, for papers by Carlos D. Figueroa Breakdown of academic impact, for papers by Ludovic Martin Breakdown of academic impact, for papers by Hiroyuki Matsuno Breakdown of academic impact, for papers by Keiichi Enjyoji